A to Z / Metabolic / weight loss
Cagrilintide
Also known as AM833, long-acting amylin analogue.
Best known for The amylin half of CagriSema
Evidence★★★☆☆
Safety dataPoorly characterised
Route Weekly injection
United StatesInvestigational
AustraliaNot approved
as at 16 September 2026
What it is
Cagrilintide is a long-acting analogue of amylin, a hormone co-secreted with insulin that signals fullness. It is an investigational medicine with phase-2 data and phase-3 work under way, not approved anywhere yet. It is best known as one half of the combination drug CagriSema.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with CagriSema, Semaglutide, Pramlintide, Tirzepatide
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Cagrilintide. It is not medical advice and not a recommendation to use it.